GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNFα INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

被引：0
|
作者：
Deodhar, Atul [1 ]
Helliwell, Philip [2 ]
Boencke, Wolf-Henning [3 ]
Hsia, Elizabeth C. [4 ,5 ,6 ]
Kollmeier, Alexa P. [4 ,5 ]
Subramanian, Ramanand A. [4 ,5 ]
Xu, Xie L. [4 ,5 ]
Sheng, Shihong [4 ,5 ]
Zhou, Bei [4 ,5 ]
Zazzetti, Federico [7 ]
Ritchlin, Christopher [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Geneva Univ Hosp, Geneva, Switzerland
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Janssen Res & Dev LLC, San Diego, CA USA
[6] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[7] Janssen LATAM Med Affairs, Buenos Aires, DF, Argentina
[8] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
298
引用
收藏
页码：24 / 24
页数：1
相关论文
共 50 条
  • [31] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled study
    Mease, Philip
    van der Heijde, Desiree
    Ritchlin, Christopher
    Cuchacovich, Rachel
    Shuler, Catherine
    Lin, Chen-Yen
    Vangerow, Harald
    Samanta, Suvajit
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
  • [32] Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher T.
    Gottlieb, Alice B.
    McInnes, Iain B.
    Puig, Lluis
    Rahman, Proton
    Li, Shu
    Wang, Yuhua
    Doyle, Mittie K.
    Mendelsohn, Alan
    Kavanaugh, Arthur
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1080 - S1081
  • [33] EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE: 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY
    Mease, P.
    Fleischmann, R.
    Wollenhaupt, J.
    Deodhar, A.
    Kielar, D.
    Woltering, F.
    Stach, C.
    Hoepken, B.
    Arledge, T.
    van der Heijde, Desiree
    RHEUMATOLOGY, 2013, 52 : 162 - 163
  • [34] Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis
    Gottlieb, Alice B.
    McInnes, Iain B.
    Rahman, Proton
    Kollmeier, Alexa P.
    Xu, Xie L.
    Jiang, Yusang
    Sheng, Shihong
    Shawi, May
    Chakravarty, Soumya D.
    Lavie, Frederic
    Mease, Philip J.
    RMD OPEN, 2023, 9 (01):
  • [35] SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-IR PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)
    Kavanaugh, A.
    McInnes, I. B.
    Hall, S.
    Chinoy, H.
    Kivitz, A.
    Kandala, S.
    Patekar, M.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 345 - 346
  • [36] Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naive Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
    Fiore, Stefano
    Genovese, Mark
    Fan, Chunpeng
    Decktor, Dennis
    Fleischmann, Roy
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1217 - 1217
  • [37] Efficacy and Safety of Tildrakizumab, a High-Affinity Anti-Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study
    Mease, Philip
    Chohan, Saima
    Garcia Fructuoso, Ferran J.
    Gottlieb, Alice
    Luggen, Michael
    Rahman, Proton
    Raychaudhuri, Siba
    Chou, Richard
    Mendelsohn, Alan
    Rozzo, Stephen
    Orbai, Ana-Maria
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [38] Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
    McInnes, I.
    Sieper, J.
    Braun, J.
    Emery, Paul
    van der Heijde, D.
    Isaacs, J.
    Dahmen, G.
    Wollenhaupt, J.
    Schulze-Koops, H.
    Gsteiger, S.
    Bertolino, A.
    Hueber, W.
    Tak, P. P.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S306 - S306
  • [39] LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Gladman, D. D.
    Starr, M.
    Ranza, R.
    Bravo Perdomo, A. M.
    Strauss, M.
    Shawi, M.
    Han, C.
    Rampakakis, E.
    Ostor, A. Andrew
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1765 - 1765
  • [40] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
    Gladman, Dafna
    Starr, Michael
    Ranza, Roberto
    Perdomo, Ana-Maria Bravo
    Strauss, Marcie
    Shawi, May
    Han, Chenglong
    Rampakakis, Emmanouil
    Ostor, Andrew
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4175 - 4178
12345